Press Release


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Spectrum Pharmaceuticals to Present at the 26th Annual Westergaard SmallCap Conference on November 11th

November 6, 2003 at 12:00 AM EST
Spectrum Pharmaceuticals to Present at the 26th Annual Westergaard SmallCap Conference on November 11thThursday November 6, 12:30 pm ET

IRVINE, CA--(MARKET WIRE)--Nov 6, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it will present at the 26th annual Westergaard SmallCap Conference on November 11, 2003, in New York City. Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President, and Gino Lenaz, M.D., President Oncology Division, will present on behalf of Spectrum Pharmaceuticals.

Paulson Investment Company, Inc. (Paulson Investment), a provider of investment banking services to small and emerging growth companies, will host the Westergaard SmallCap Conference in New York City on Nov. 11. Founded in 1978 by John Westergaard, this conference provides emerging growth companies with a forum for presenting to investment professionals and offers insights into trends in the smallcap marketplace. This unique forum allows entrepreneurs in a variety of sectors, including technology, biotechnology, security and media, to make presentations on the state of their businesses.

The conference will take place at the Waldorf-Astoria in New York City on Tuesday, Nov. 11 from 9 a.m. to 5 p.m., with a closing reception from 5:30 p.m. to 7:30 p.m. The luncheon keynote speaker is Lawrence Kudlow, CNBC commentator and co-host of "Kudlow and Cramer." For more information, visit

Spectrum Pharmaceuticals' primary focus is to develop in-licensed drugs for the treatment and supportive care of cancer patients. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG, which has been granted fast-track status by the United States Food and Drug Administration. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. Eoquin™ is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company is actively working to develop, seek approval for and oversee the marketing of generic drugs in the U.S. Spectrum also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co-develop. For additional information about the Company, visit the Company's Web site at

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to the intent, belief, plans or expectations of the company or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include our lack of revenues and need for additional financing, the possibility that our existing drug product candidates may not prove to be safe or effective, our limited experience in establishing strategic alliances, our limited experience with the generic drug industry and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission.


For further information, please contact:

John McManus
Spectrum Pharmaceuticals, Inc.
(949) 788-6700, ext. 247